ValueAct Capital Portfolio in 2026: Top Holdings & Recent Changes
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
ValueAct Capital, the activist investment firm led by Mason Morfit, launched its aggressive strategy with a complete portfolio overhaul in its inaugural 13F filing. The firm's Q3 2006 portfolio totals $3.7 million across 26 new positions, showcasing high-conviction buys in overlooked information services, technology, and healthcare names that screamed turnaround potential.
Portfolio Overview: A Bold Launchpad for Activist Value Creation
Portfolio Highlights (Q3 2006): - Market Value: $3,747.5K - Top 10 Holdings: 76.2% - Portfolio Size: 26 +26 - Average Holding Period: 1 quarter - Turnover: 100.0%
ValueAct Capital's Q3 2006 portfolio reflects a clean-slate approach, with 100% turnover indicating every position is a fresh "Buy" amid the firm's early activist phase. The extreme concentration—76.2% in just the top 10—underscores a high-conviction strategy typical of activist investors who target undervalued companies ripe for operational improvements. At a modest $3.7 million market value, this filing captures ValueAct's nimble startup phase, building a diversified yet focused foundation across 26 names rather than chasing mega-caps.
The 1-quarter average holding period and full turnover signal rapid deployment rather than long-term patience at this stage, likely testing theses in a post-dot-com recovery market. ValueAct's portfolio structure prioritizes position sizing based on perceived unlock potential, with the top holding at 11.6% dwarfing the rest. This setup allows flexibility for quick pivots while maintaining firepower for deeper engagements.
Top Holdings: Information Services and Tech Turnarounds Take Center Stage
ValueAct's portfolio kicks off with massive new stakes across diverse sectors, prioritizing companies with strong data, software, and services moats. Leading the pack is REUTERS GROUP PLC ORD 25P as the top buy at 11.6% $433.5K, a bold international media play signaling bets on information dominance. Close behind, Gartner, Inc. (IT) claims 9.7% $362.9K as a fresh Buy, highlighting early conviction in IT research and advisory amid enterprise tech spending.
The momentum continues with AVAYA INC at 9.5% ($356.5K Buy), a telecom equipment name positioned for enterprise voice recovery, followed by REYNOLDS & REYNOLDS CO CL A (8.4%, $313.8K Buy) in automotive software and MDS INC (7.6%, $284.0K Buy) tapping nuclear medicine and health diagnostics. ACXIOM CORP rounds out the mid-tier at 6.8% ($254.6K Buy), a data marketing specialist, while VALEANT PHARMACEUTICALS INTL (6.2%, $233.9K Buy) enters healthcare with aggressive pharma positioning.
Lower in the top 10 but still significant, SEITEL INC NEW and CATALINA MARKETING CORP both hit 6.2% and 5.3% respectively as new Buys ($232.3K and $199.3K), focusing on seismic data and retail marketing tech. Closing the list, HANOVER COMPRESSOR CO at 4.9% ($185.1K Buy) adds energy services exposure. These 10 positions alone command 76.2% of the ValueAct portfolio, blending tech services with niche industrials for balanced activist targets.
Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.
Want to see what we'll uncover next - before everyone else does?
Find Hidden Gems First!
What the Portfolio Reveals About ValueAct's Activist Blueprint
ValueAct's Q3 2006 snapshot unveils a classic activist playbook: targeting undervalued mid-caps with operational catalysts in information-intensive sectors.
- Sector Focus on Data and Tech Services: Heavy weighting in IT research (IT), media (REUTERS), and data firms like Acxiom reveals a thesis on information asymmetry unlocks.
- Turnaround Specialization: Buys in telecom (AVAYA), pharma (VALEANT), and energy services point to companies needing management shakeups or efficiency drives.
- Geographic and Niche Diversification: International picks like Reuters balance U.S.-centric tech and healthcare, mitigating single-market risk.
- Risk Management via Concentration: 76% top-10 tilt amplifies winners but demands deep due diligence, with 26 total positions providing modest breadth.
- High Turnover as Opportunity Capture: 100% churn reflects a dynamic hunt for fresh mispricings in a recovering 2006 market.
Portfolio Concentration Analysis
| Position | Value | % of Portfolio | Recent Change |
|---|---|---|---|
| REUTERS GROUP PLC ORD 25P | $433.5K | 11.6% | Buy |
| Gartner, Inc. | $362.9K | 9.7% | Buy |
| AVAYA INC | $356.5K | 9.5% | Buy |
| REYNOLDS & REYNOLDS CO CL A | $313.8K | 8.4% | Buy |
| MDS INC | $284.0K | 7.6% | Buy |
| ACXIOM CORP | $254.6K | 6.8% | Buy |
| VALEANT PHARMACEUTICALS INTL | $233.9K | 6.2% | Buy |
| SEITEL INC NEW | $232.3K | 6.2% | Buy |
| CATALINA MARKETING CORP | $199.3K | 5.3% | Buy |
| HANOVER COMPRESSOR CO | $185.1K | 4.9% | Buy |
This table illustrates ValueAct's razor-sharp focus, with the top 10 commanding 76.2% of the $3.7M portfolio—all fresh Buys signaling uniform high conviction from inception. The smooth decline from 11.6% to 4.9% shows disciplined sizing, avoiding over-reliance on any single name while prioritizing perceived alpha generators like Reuters and Gartner.
The absence of legacy holdings (100% turnover) underscores an activist's willingness to reset aggressively, positioning for quick influence in underfollowed names. For 2006 context, this concentration amplified exposure to tech recovery plays, balancing risk through sector spread.
Investment Lessons from ValueAct Capital's Activist Approach
ValueAct's Q3 2006 portfolio demonstrates timeless principles from its activist heritage:
- Hunt Mispriced Niches: Prioritizing data/services firms like Gartner and Acxiom shows value in overlooked moats over trendy megacaps.
- Size for Conviction, Diversify for Survival: 76% top-10 concentration demands thesis confidence, buffered by 26 positions.
- Embrace High Turnover Early: 100% churn captures fleeting opportunities, evolving as the firm scales.
- Target Operational Catalysts: Every Buy screams turnaround—telecom, pharma, energy—where activism unlocks value.
- Start Small, Think Big: A $3.7M filing belies future billions, proving nimble beginnings build empires.
Looking Ahead: What Comes Next?
With a brand-new 26-position book and 100% turnover, ValueAct likely held dry powder for Q4 2006 expansions, especially if early buys like IT or Reuters delivered. The mid-cap focus sets up for 2007's credit boom, targeting more services/tech amid housing peaks. Favorable conditions—low rates, M&A wave—align with activist pushes, while the portfolio's data-heavy tilt hedges economic shifts. Track via ValueSense for evolution from this launchpad.
FAQ about ValueAct Capital Portfolio
Q: What were the biggest new positions in ValueAct's Q3 2006 13F?
A: All top holdings were fresh Buys, led by REUTERS GROUP PLC ORD 25P 11.6%, Gartner (IT) 9.7%, and AVAYA INC 9.5%, building a concentrated activist foundation.
Q: Why such high concentration and turnover in this early filing?
A: 76.2% top-10 weighting and 100% turnover reflect ValueAct's activist DNA—high-conviction bets on turnarounds with flexibility to pivot, ideal for a startup portfolio in 2006's recovering market.
Q: What sectors does ValueAct emphasize here?
A: Information services (Reuters, Gartner), tech/telecom (Avaya, Reynolds), healthcare (MDS, Valeant), and energy/data niches dominate, targeting undervalued operational improvements.
Q: How can I track ValueAct Capital's portfolio today?
A: Follow quarterly 13F filings on ValueSense at https://valuesense.io/superinvestors/valueactcapital for updates, visualizations, and changes—note the 45-day reporting lag means real-time positions may differ.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2026)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!